Purpose Male breast cancer (BC) is rare, representing approximately 1% of cancers that
occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not …

Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

Background Male breast cancer (BC) is rare, managed by extrapolation from female BC. The
International Male BC Program aims to better characterize and manage this disease. We …

Abstract On April 4, 2019, the FDA approved a supplemental new drug application for
palbociclib (IBRANCE), to expand the approved indications in women with hormone …

Although similar phenotypically, there is evidence that male and female breast cancer differ
in their molecular landscapes. In this systematic review, we consolidated all existing …

Simple Summary Male breast cancer is a rare disease, representing around 0.5% of the
malignances in men. Although they receive the same treatment as women with breast …

Background Male breast cancer (MBC) is a rare disease for which no randomised controlled
trials (RCT) have been conducted to determine optimal surgical management. The available …

Simple Summary Male breast cancer (MBC) is a rare disease. Genetic factors predispose to
male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic …

Background: Invasive breast cancer (IBC) can be categorized into prognostic and predictive
molecular subtypes (including luminal breast cancer) using gene expression profiling …

Breast cancer prognosis and management for both men and women are reliant upon
estrogen receptor alpha (ERα) and progesterone receptor (PR) expression to inform …